Protagonist Therapeutics reports Q1 EPS $3.26, consensus $1.19

Reports Q1 revenue $254.95M, consensus $120M. “The first quarter of 2024 was an extremely busy and productive time for Protagonist,” said Dinesh Patel, the Company’s President and CEO. “We announced a transformational partnership with Takeda to develop and commercialize rusfertide that allows us to reinvest in our core competency in peptide therapeutics and expand our efforts to create a new pipeline of potential blockbusters and highly differentiated development candidates. We expect to nominate an oral IL-17 antagonist development candidate this year from our internal discovery efforts.”